Member Info for nursesteve

I don’t expect details of ‘confidential exploratory discussions’ to be revealed just what they result in - Smon has been involved in over 80 deals so ?

News could (and should) land anytime soon. We know the update on the first cohort of the two weekly trial is overdue but also I’d expect to hear what Simon has been up to (having been told by both CC and Al that he has been very busy). GLA

Plus

- FDA fast track approval

Everything on the table could also include:

- Sell off / spin off diagnostics

- Inter day RNS?

+?

*Thursday RNS

Probably not but soon Rodders soon!

The RNS announcement of Christina Coughlin, MD, PhD, being appointed Chief Executive Officer of Avacta Group stated that “Appointment reflects Avacta's focus on maximizing value from the pre|CISIONTM platform for the treatment of cancer”.

This to me seems to be a clear move away from the previous CEO who was focusing to much on the diagnostic division and acknowledging the mistake he made to plunge more funds into adding loss making business to that division while the clear value driver seems clear to others to be development of the pre|CISION™ platform.

Dr. Coughlin assumed the role of Head of Research and Development in February 2024, driving the development of the pre|CISION™ platform.

“ The Group’s strategy is to divest the Diagnostics Division to create a pure-play oncology biopharmaceutical company in a manner which maximises value and strategic benefits for shareholders.” Good on you Chris!

Nice to see this “ Avacta seeks to create long-term shareholder value alongside patient benefit.” putting SH value first and foremost

This is currently a loss making business. A change in strategy is needed which I hope the change in CEO indicates. On the to do list I’d like to see them divest the diagnostic business and use the funds to pay off the bond plus get some deals in place to become cash generative - you can’t be too picky while we are bleeding cash.

They might be keeping the update back till tomorrow (on reviewing the first cohort of the 2 weekly trial) for CC to release - thereby turning the page and putting her own stamp on how best to be updating SH on AVACTA progress with AVA6000 and how best to maximise the value?

Good luck to you sheppy / I’m in Dubai currently by a pool looking at the Burj Khalifa & I’m travelling round the south of France for a month in a couple of weeks time - no permanent oversea residences for me but I’m happy staying in Avacta! 🥂 and certainly hope the shorters here get burned next week GL

Yes one of the more dubious calls being spending more money on acquisitions to add to the diagnostic side when the clear value driver seemed to already be proven through AVA6000!

News could also be from Dr Simon Bennett the Chief Business Officer bringing his 26 years' commercial experience in the biopharma industry (so hopefully more competent than todays RNS authors). Simon has worked with companies from large and mid-sized pharma such as Bristol-Myers-Squibb and Menarini Group to early stage biotechs, supporting business development and licensing activities in addition to being involved in all aspects of business and corporate development. Simon has been involved in over 80 (soon to be 81?) commercial deals across Europe, North America, Australasia, Japan, Russia/CIS and South America. 🤝GLA

Definitely taking the p now “ These arrangements continue to align the interest of the Executive Directors with the longer-term share price performance interests of our shareholders.”

I’ve submitted a question asking how well they think they’re doing on their mission statement about growing shareholder value? & when we might see value reflected in the share price.

Yorkshire - Looking at what the Dec RNS stated, to increase efficacy data is what the two weekly study has been designed for - “The next steps with AVA6000 involve optimising the patient population, dose and schedule in order to increase efficacy and tolerability of doxorubicin treatment via pre|CISIONTM targeting. That Dec RNS also stated that safety data had been obtained and this has later been reported at the AACR conference along with the unexpected efficacy data from the 3 weekly study (unexpected because this population wasn’t selected for efficacy - which I believe the two weekly population will have been selected for) we have been told the first cohort weekly cohort data will be reviewed at the end of the month by the SDMC so hopefully on the cusp?

Wyndrum - the FDA may be unwilling to grant AA in the basis of the safety data alone as this is what phase 1 trials are all about usually - the pivot to unexpected 2 weekly may be to provide greater efficacy data which could trigger AA?

Yorkshirepragma looking at the document you posted the link to, at the bottom of the table on page 3 seems to be likely where we are with AVA6000 - on the cusp of AA. After phase 1 but before phase 2?

It also mentions the FDA can grant AA and approve drugs purely on the basis of tumour reduction - a surrogate endpoint. A threshold we seem to have reached and this two weekly trial might be the pivot towards providing the data that the FDA would need?

Yes Thornogson but also this might be the whole reason for the two weekly trial to prove decisive data to the FDA for accelerated approval? We know Avacta have been in discussions with the regulators and they have hosted big pharma. It could all change very quickly.